Europe
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
In its CRL, the FDA identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications.
In June, it dosed its first two patients using a novel therapeutic, AMT-130, delivered directly to the brain. Initial readouts are expected in a year’s time.
Russia’s minister of health, Mikhail Murashko, indicated that the country plans a nationwide program to vaccinate its population against COVID-19 starting in October.
Eight months after inking a collaboration deal, MorphoSys and Incyte won approval for Monjuvi for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.
As usual, there was plenty of clinical trial news last week. Here’s a look.
GlaxoSmithKline and Sanofi struck a $2.1 billion deal with the U.S. government’s Operation Warp Speed program to supply an initial 100 million doses of a COVID-19 vaccine candidate under development by the two companies.
Genomic medicine company Sangamo Therapeutics announced today that it has entered a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies for three neurodevelopmental targets, including autism spectrum disorder.
PRESS RELEASES